Dopamine D1–D5 Receptors in Brain Nuclei: Implications for Health and Disease
Article in Receptors (April 2024)
The most recent citing publication is shown below. View this citation on Dimensions.
Therapeutic Applications of Dopamine D3 Receptor Function
Overview of attention for book
Table of Contents
-
Altmetric BadgeBook Overview
-
Altmetric BadgeChapter 314 Location, Location, Location: The Expression of D3 Dopamine Receptors in the Nervous System
-
Altmetric BadgeChapter 315 A Historical Perspective on the Dopamine D3 Receptor
-
Altmetric BadgeChapter 316 Dopamine D3 Receptors: A Potential Target to Treat Motivational Deficits in Parkinson’s Disease
-
Altmetric BadgeChapter 326 Dopamine D3 Receptor, Cognition and Cognitive Dysfunctions in Neuropsychiatric Disorders: From the Bench to the Bedside
-
Altmetric BadgeChapter 347 Current Perspectives on Selective Dopamine D3 Receptor Antagonists/Partial Agonists as Pharmacotherapeutics for Opioid and Psychostimulant Use Disorders
-
Altmetric BadgeChapter 348 Involvement of DA D3 Receptors in Structural Neuroplasticity of Selected Limbic Brain Circuits: Possible Role in Treatment-Resistant Depression
-
Altmetric BadgeChapter 351 D3 Receptors and Restless Legs Syndrome
-
Altmetric BadgeChapter 353 Recent Advances in Dopamine D3 Receptor Heterodimers: Focus on Dopamine D3 and D1 Receptor–Receptor Interaction and Striatal Function
-
Altmetric BadgeChapter 373 Dopamine D3 Receptor in Parkinson Disease: A Prognosis Biomarker and an Intervention Target
-
Altmetric BadgeChapter 374 D3 Receptors and PET Imaging
-
Altmetric BadgeChapter 392 The Role of Dopamine D3 Receptors in Tobacco Use Disorder: A Synthesis of the Preclinical and Clinical Literature
Attention for Chapter 347:
Current Perspectives on Selective Dopamine D3 Receptor Antagonists/Partial Agonists as Pharmacotherapeutics for Opioid and Psychostimulant Use Disorders